Angioplasty.Org
Most Popular Angioplasty Web Site
    Angioplasty.Org
News Center
Features, Commentary, Interviews, Company News
Email Bookmark and Share
If you wish to view news by a specific topic or date range, select from the following menu:

June 25, 2014
Study Published in The New England Journal of Medicine Finds Medtronic Insertable Cardiac Monitors Detect Atrial Fibrillation in Stroke Patients Better Than Standard Care
Medtronic's Reveal XT Insertable Cardiac Monitor
Medtronic, Inc. (NYSE: MDT), today announced results from the CRYSTAL AF (CRYptogenic STroke And underLying Atrial Fibrillation) Clinical Trial have been published in The New England Journal of Medicine. The Trial found that continuous cardiac monitoring with the Reveal® XT Insertable Cardiac Monitor (ICM) was superior to standard care at detecting atrial fibrillation (AF) in patients who have had strokes of undetermined causes (cryptogenic stroke).

June 19, 2014
Medtronic Announces Preliminary Outcomes for World's Smallest Cardiac Pacemaker
Micra pacemaker in heart
Medtronic, Inc. (NYSE: MDT) today announced preliminary results from the first human implants of the world's smallest pacemaker, the Micra™ Transcatheter Pacing System (TPS). Results from the first four patients to receive the Micra TPS were reported at CARDIOSTIM / EHRA EUROPACE 2014, World Congress in Electrophysiology and Cardiac Techniques, in Nice, France. At 1 month and 3 months, results showed the Micra TPS was successfully implanted in all patients, whose ages ranged from 74 to 83 years, and there were no major complications post-implant. The device performed as expected, and electrical values were within normal ranges.

June 12, 2014
Medtronic CoreValve System Receives FDA Approval for Patients at High Risk for Surgery
CoreValve in situ
Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the self-expanding transcatheter CoreValve® System for patients with severe aortic stenosis who are at high risk for surgery.This approval is based on groundbreaking research that showed clinical outcomes at one year with the CoreValve System were superior to open-heart surgery, the current gold standard for aortic valve replacement. The FDA approved the CoreValve System without the need for an independent device advisory panel review due to its exceptionally positive clinical results demonstrated in the High Risk Study of the CoreValve U.S. Pivotal Trial.

June 11, 2014
Medtronic Submits Final Data to FDA for Novel Device to Treat Peripheral Artery Disease
IN.PACT Admiral drug-coated balloon
Medtronic, Inc. (NYSE: MDT) today announced that it recently submitted the final module of its pre-market approval (PMA) application for the IN.PACT Admiral drug-coated balloon to the U.S. Food and Drug Administration (FDA). The application includes data that demonstrates superior clinical outcomes compared with conventional angioplasty, with the lowest rates of repeat procedures (target lesion revascularization) and the highest rate of uninterrupted blood flow (primary patency) at 12 months ever reported for the interventional treatment of peripheral artery disease.

June 4, 2014
Medtronic Expands Availability of Market-Leading Aortic & Peripheral Solutions to U.S. Market
Valiant Captivia
Medtronic, Inc. (NYSE: MDT) announced today that two recently Food and Drug Administration (FDA) approved devices will be featured at the Society for Vascular Surgery's 2014 Vascular Annual Meeting, taking place June 5-7 in Boston. Valiant Captivia Thoracic Stent Graft system proximal FreeFlo tapers line extension now with dissection indication, and the TOTAL across crossing support catheter for peripheral artery disease (PAD) in the below-the-knee (BTK) vessel bed are now available to physicians in the United States.

June 3, 2014
Volcano Corporation Schedules Conference Call, Webcast To Discuss iFR® Technology Market Opportunity
iFR diagram
Volcano Corporation (Nasdaq: VOLC) said today that it will be holding a conference call and webcast to discuss the market expansion opportunity for its iFR (instant wave-Free Ratio™) technology on Thursday, June 5. The presentation by John Dahldorf, chief financial officer, and Joseph Burnett, executive vice president, coronary and systems business unit, will begin at 1:30 p.m., Pacific Daylight Time (4:30 Eastern Daylight Time).

Jun 2, 2014
Volcano Corporation Presentation At Goldman Sachs Healthcare Conference To Be Webcast
Rancho Palos Verdes, CA
Volcano Corporation (Nasdaq: VOLC), a platform company providing and guiding minimally invasive therapies utilizing visualization, physiology or future technologies, said today that it will be participating in the Goldman Sachs 35th Annual Global Healthcare Conference on Tuesday, June 10. The presentation by John Dahldorf, chief financial officer, will begin at 11:20 a.m., Pacific Daylight Time (2:20 p.m., Eastern Daylight Time)

May 27, 2014
Volcano Corporation Announces Agreement To Acquire AtheroMed
AtheroMed's Phoenix Atherectomy System
Volcano Corporation (Nasdaq: VOLC) said today it has signed an agreement to acquire AtheroMed, Inc., a privately-held company that has developed the Phoenix® Atherectomy System used in the treatment of peripheral artery disease (PAD). The Phoenix, which received 510(k) clearance in January 2014 and has a CE Mark, enables physicians to treat PAD with a low profile peripheral atherectomy catheter that continuously removes diseased material as it is debulked. The device has reimbursement in the U.S. and select countries in Europe.

May 21, 2014
Medtronic CoreValve® System Demonstrates Positive Clinical Performance at Two Years in 'Real World' ADVANCE Study
Medtronic's CoreValve
Medtronic, Inc. (NYSE: MDT) today revealed new data showing that patients treated with the CoreValve® System experienced positive clinical outcomes in the rigorous "real world" Medtronic CoreValve ADVANCE Study. Two-year follow-up was reported on 96.8 percent of 1,015 patients, all of whom had severe aortic stenosis and were treated with the CoreValve System. Patients experienced low rates of all-cause mortality (25.6 percent), cardiovascular mortality (16.8 percent) and major stroke (2.9 percent) at two years.

May 20, 2014
Medtronic Announces CE Mark and Launch of NC Euphora™ Coronary Balloon
Continuing its commitment to bringing advanced and clinically relevant interventional technologies to market, Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européene) mark and launch of the NC Euphora™ Noncompliant Balloon Dilatation Catheter. The NC Euphora Balloon Catheter is now available in Europe and other countries outside of the United States that recognize the CE mark. It is not yet available in the United States.

May 20, 2014
Medtronic Reports Fourth Quarter and Fiscal Year 2014 Earnings
Medtronic logo
Medtronic, Inc. (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2014, which ended April 25, 2014. The company reported worldwide fourth quarter revenue of $4.566 billion, compared to the $4.459 billion reported in the fourth quarter of fiscal year 2013, an increase of 3 percent on a constant currency basis after adjusting for a $39 million negative foreign currency impact or 2 percent as reported.

May 20, 2014
Medtronic Settles Global Patent Litigation with Edwards Lifesciences
Medtronic and Edwards logos
Medtronic, Inc. (NYSE: MDT) announced that it has reached a global patent settlement agreement with Edwards Lifesciences Corporation (NYSE:EW). Under the terms of the cross-license settlement agreement, the parties will dismiss all of the pending litigation matters and patent office actions between them, and grant each other broad releases to patent litigation claims. Medtronic will pay Edwards a one-time payment of $750 million, and ongoing royalty payments through April 2022 based on a percentage of CoreValve sales, in payments of no less than $40 million annually.

May 13, 2014
SCAI and CRF Training Programs in Transradial PCI
Diagram of Radial Artery
The next few months offer some unique training opportunities for the U.S. interventional cardiologist regarding the transradial approach to catheterization, angioplasty and stent implantation via the wrist artery.



May 5, 2014
Volcano Corporation Presentation At Bank Of America Merrill Lynch 2014 Health Care Conference To Be Webcast
Encore at Wynn Resort, Las Vegas
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13. The presentation by John Dahldorf, chief financial officer, will begin at 4:20 p.m., Pacific Daylight Time (7:20 p.m., Eastern Daylight Time).


May 4, 2014
Abbott's MitraClip Approved in Canada
MitraClip from Abbott Vascular
Abbott (NYSE: ABT) has announced that its MitraClip Delivery System has been approved in Canada for use in patients "with degenerative mitral regurgitation who are too high risk for mitral valve surgery based on evaluation by a team of heart doctors, including a heart surgeon." The ruling by Health Canada now allows sale of the MitraClip throughout the country; the MitraClip was approved by the FDA for use in the United States last October.

May 2, 2014
Volcano Reports First Quarter Results
Volcano Corporation Headquarters in San Diego
Volcano Corporation (Nasdaq: VOLC) today reported results for the first quarter of 2014. For the quarter ended March 31, 2014, Volcano reported revenues of $94.5 million versus revenues of $93.2 million in the same period a year ago. On a constant currency basis, revenues increased four percent year-over-year after adjusting for a negative impact of approximately $2.7 million from foreign currency.

April 29, 2014
Medtronic Reveals Positive Outcomes for CoreValve® Patients Treated via Alternative Access Routes
Medtronic's CoreValve
Medtronic, Inc. (NYSE: MDT) today revealed new data demonstrating positive outcomes for extreme risk patients with severe aortic stenosis who were treated with the CoreValve® System via alternative access approaches. The study evaluated 150 patients from the CoreValve U.S. Pivotal Trial (23 percent of the extreme risk patient group) who were not suitable for traditional transcatheter aortic valve replacement (TAVR) through the femoral artery, and therefore were treated via subclavian or direct aortic approaches.

April 25, 2014
Volcano Announces Limited Market Release of SyncVision™ Technology System
Volcano Logo
Volcano Corporation (NASDAQ: VOLC) today announced the commencement of its limited market release of its FDA cleared and CE marked technology SyncVision™, with cases being performed in the U.S. and Europe. SyncVision™ is currently installed in multiple limited market release sites throughout U.S. and Europe. Volcano's SyncVision™ Technology System is an on-line image processing workstation for coronary catheterizations that allows the physician to navigate simultaneously on an angiogram and on an IVUS image in a single correlated view using co-registration of the Eagle Eye® Platinum catheter with x-ray angiography.

April 21, 2014
Edwards Lifesciences Comments on U.S. Appeals Court Order
Edwards and Medtronic logos
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced that the U.S. Court of Appeals for the Federal Circuit today issued a stay for the preliminary injunction that was ordered on April 11 to limit the sale of Medtronic's CoreValve system in the United States. Today's order postpones the implementation of the preliminary injunction. It does not reverse the federal jury's finding of Medtronic's willful infringement, for which all appeals have been exhausted, and does not affect the determination of additional damages.

April 21, 2014
Federal Appeals Court Agrees to Medtronic Request to Postpone Injunction
Medtronic's CoreValve
The Federal Circuit Court of Appeals today granted a request from Medtronic, Inc. (NYSE: MDT) to postpone the implementation of an injunction that would have prevented the company from selling its CoreValve® System in the United States. This means the injunction will only take effect if the appellate court determines the injunction was properly issued. In addition, last week the Court of Appeals agreed to an expedited appeal of the injunction ruling, with the last appeal brief to be submitted by June 19.

April 19, 2014
Update on CoreValve Federal District Court Ruling; Court Agrees to Expedited Appeal
CoreValve and Gavel
Medtronic, Inc. (NYSE: MDT) today issued an updated statement on the recent ruling by Federal District Court of Delaware. Medtronic has asked the U.S. Circuit Court of Appeals to postpone the injunction until it can determine if the injunction was properly issued. The Court has not yet ruled. Medtronic also requested, and the Court agreed to, an expedited appeal of the injunction ruling, and other underlying legal issues, with the last appeal brief to be submitted by June 19. Medtronic does not believe Edwards Lifesciences, which brought the motion for a preliminary injunction, has met the standards needed for an injunction, particularly with respect to the impact it will have on the public health interest.

April 18, 2014
Endurant AAA Stent Graft from Medtronic Continues Exceptional Long-Term Performance in Observational Studies
Endurant AAA stent graft
The Endurant AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to demonstrate exceptional long-term performance in the endovascular treatment of abdominal aortic aneurysms, according to new clinical data from two separate observational studies -- PANDORA, independently conducted at two sites in Germany; and ENGAGE, sponsored by Medtronic and involving 79 sites worldwide.

April 17, 2014
MARS Across the Hudson: Mid-Atlantic Radial Symposium is May 3
Dr. Jordan Safirstein and his Google Glass
If you are an interventional cardiologist or work in a cath lab where the transradial approach is being utilized, and you live anywhere near New York-New Jersey-Pennsylvania, you might want to consider a day trip to Morristown, New Jersey on May 3. This trip won't cost you anything, because the Mid-Atlantic Radial Symposium (MARS) is free; and yes, there still is such a thing as a free lunch.

April 17, 2014
Volcano Corporation Schedules First Quarter Conference Call, Webcast
Scott Huennekens, President & CEO, Volcano Corporation
Volcano Corporation (Nasdaq:VOLC) announced that it will report its operating results for the first quarter of fiscal 2014 on Friday, May 2. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 pm, Pacific Daylight Time (5 pm, Eastern Daylight Time), Friday, May 2, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer.

April 14, 2014
Valve Wars, Part III: Edwards vs. Medtronic
Medtronic and Edwards logos
Another volley across the bow in the ongoing heart valve wars was served up Friday, when the U.S. District Court for the District of Delaware granted Edwards Lifesciences (NYSE: EW), the manufacturer of the Sapien transcatheter aortic valve, a preliminary injunction that will limit Medtronic's (NYSE: NDT) sales of its competing CoreValve system in the United States. Barring further rulings, the injunction will go into effect on April 22.

April 11, 2014
FDA Approves Start of Trial for Cobra PzF™ Stent
close-up of COBRA PzF stent surface
A clinical trial for a novel concept coronary stent will soon start enrolling patients in the United States: the COBRA PzF™ coronary stent system was given an investigative device exemption (IDE) by the FDA last month and will shortly begin recruiting at 14 U.S. hospitals; 13 outside U.S. sites have already started the process.


April 10, 2014
Abbott's Absorb Bioresorbable Scaffold Completes Enrollment in 3 Pivotal Clinical Trials
Abbott Absorb Bioresorbable Scaffold
Today, Abbott announced that it has completed enrollment of not one, but three pivotal clinical trials to support approval of the Absorb BVS in the United States, Japan, and China, three countries that comprise 50% of the global market for stents. The trials pit the Absorb Bioresorbable Vascular Scaffold against Abbott's flagship everolimus-eluting XIENCE stent in almost 3,000 patients worldwide.

April 5, 2014
'IN.PACT Admiral' Drug-Coated Balloon From Medtronic Outperforms Standard Angioplasty In Landmark Study
IN.PACT Admiral Drug-Eluting Balloon
Patients with peripheral artery disease in the upper leg experienced significantly better outcomes at 12 months after treatment with the IN.PACT Admiral drug-coated balloon from Medtronic, Inc. (NYSE: MDT) than with standard balloon angioplasty, according to a landmark clinical study reported on today for the first time. The IN.PACT SFA Trial enrolled 331 subjects at 57 sites across Europe and the United States.

March 31, 2014
Medtronic CoreValve® System Demonstrates Long-Term Durability
Medtronic's CoreValve
The Study results showed the long-term durability and excellent clinical performance of the CoreValve System with no incidences of structural valve dysfunction at four years. The study also showed significant improvements in quality of life at one year which were sustained through four years, with 74 percent of patients improving at least one New York Heart Association (NYHA) functional class from baseline to four years. Additionally, the rates of regurgitation and stroke remained low, with 83.0 percent of patients free from stroke at four years follow-up.

March 30, 2014
World's First Transcatheter Valve, Medtronic Melody® Transcatheter Pulmonary Valve Shows Positive Clinical Outcomes in Real-World Study
Melody® Transcatheter Pulmonary Valve
The Melody® Transcatheter Pulmonary Valve (TPV) U.S. Post-Approval Study found that real-world use of the Melody TPV was associated with high procedural success, excellent valve function and few repeat procedures at the primary endpoint of six months. These results were sustained out to one year. The Melody TPV was the first transcatheter valve to be approved by the U.S. Food and Drug Administration (FDA) and the first transcatheter valve available anywhere in the world. The therapy has treated more than 6,000 patients worldwide to date, more than half of whom are children with congenital heart disease (CHD).

March 30, 2014
Robot Stent Placement in the Cath Lab
Robotics in the Cath Lab
Angioplasty and stent placement is the gold standard for the emergency treatment of heart attacks. But getting the patient to a catheterization lab where the angioplasty can be performed in a timely fashion has been a challenge. Now, Corindus Vascular Robotics is testing a new solution, whereby an interventional cardiologist may be able to perform an angioplasty and precisely place a stent -- from another city!

March 30, 2014
Medtronic Global SYMPLICITY Registry Shows Strong Safety Profile of the Symplicity™ Renal Denervation System
Renal sympathetic nerves and the kidney
Medtronic, Inc. (NYSE: MDT), announced today further analysis of six-month follow-up data from the first 1,000 patients enrolled in the Global SYMPLICITY Registry, which continue to demonstrate the safety of the Symplicity™ renal denervation system. The results of this observational, open-label study show that renal denervation with the Symplicity™ renal denervation system resulted in significant reductions in both office and 24-hour ambulatory blood pressure compared to baseline, with very low adverse event rates to six months.

March 29, 2014
Boston Scientific LOTUS™ Valve System Demonstrates Sustained Safety and Efficacy Outcomes at Three Months
Professor Ian Meredith
The REPRISE II clinical trial, evaluating the Lotus™ Valve System in symptomatic patients with severe aortic valve stenosis and considered at high risk for surgical valve replacement, demonstrated favorable safety and efficacy outcomes out to three months with 85 percent of patients having no paravalvular aortic regurgitation (leaking). The data were presented by Professor Ian Meredith, director of MonashHeart at Monash Medical Centre in Melbourne, Australia, and principal investigator of the REPRISE II trial.

March 29, 2014
Medtronic CoreValve® System Results Superior to Open-Heart Surgery at One Year in U.S. Pivotal Trial
Medtronic's CoreValve
Medtronic, Inc. (NYSE: MDT) today announced that the CoreValve® System showed results superior to surgical aortic valve replacement (SAVR) at one year in the High Risk Study of its CoreValve U.S. Pivotal Trial, which evaluated patients with severe aortic stenosis who are considered high risk for surgery. The data were presented at a late-breaking clinical trial session at the 63rd Annual Scientific Session of the American College of Cardiology (ACC) and simultaneously published in The New England Journal of Medicine.

March 29, 2014
Medtronic Releases Results of SYMPLICITY HTN-3
Medtronic's Symplicity Renal Denervation System
Medtronic, Inc. (NYSE: MDT) today announced the full results of the SYMPLICITY HTN-3 clinical trial, which were presented today at the 63rd Scientific Sessions of the American College of Cardiology (ACC) and published simultaneously in The New England Journal of Medicine. SYMPLICITY HTN-3, the first and only blinded, randomized, sham controlled study of renal denervation for treatment-resistant hypertension, met its primary safety endpoint but did not meet its primary or secondary efficacy endpoints.

March 19, 2014
FDA Approves Volcano's iFR® Pressure Measurement Modality for Use in Coronary Stent Guidance
Volcano's iFR system measures intracoronary pressures without need for adenosine
This morning Volcano Corporation announced that the U.S. Food and Drug Administration has granted approval to the company's proprietary coronary pressure measurement modality, iFR (Instant wave-Free Ratio). iFR represents a significant advance in the field of functional measurement (FM), in which the actual flow pressures inside the coronary artery can be measured and the deficit caused by a coronary blockage or lesion can be accurately assessed.

March 17, 2014
Boston Scientific Gets European Approval for the REBEL: a "New" Bare Metal Stent
Boston Scientific's REBEL bare metal stent
Take away the everolimus-eluting polymer from Boston Scientific's FDA-approved Promus PREMIER™ stent and what do you have? The REBEL bare metal stent, which just received CE Mark approval last week and is now available for the European market. REBEL is probably a good name for this device, in that it "rebels" against the historical norm, wherein a bare metal stent platform first gets approved for safety and efficacy, and only then gets coated with a drug-eluting polymer, is tested in clinical trials, gets CE Mark approval and finally FDA approval.

March 10, 2014
Medtronic Seeking Long-Distance Runners Who Benefit From Medical Technology

Medtronic Global Heroes
Medtronic, Inc. (NYSE: MDT) announced today applications are open to runners around the world who benefit from medical technology to represent their country on the 2014 Medtronic Global Heroes team. The 2014 Medtronic Twin Cities Marathon weekend will take place October 3-5, 2014.


March 6, 2014
Valve Wars, Part II: Edwards vs. Medtronic
Medtronic's CoreValve
Last summer the District Court of Mannheim issued an injunction prohibiting Medtronic from selling its CoreValve and CoreValve Evolut transcatheter valves in Germany. The injunction was based on the Spenser patent. Today Medtronic announced that the European Patent Office has revoked the Spenser patent in its entirety. This outcome is a big win for Medtronic in Europe, although the ruling is subject to appeal by Edwards.

March 3, 2014
Volcano Corporation Presentation At Barclays Conference To Be Webcast
Volcano Headquarters
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the Barclays Global Healthcare Conference 2014 on Tuesday, March 11. The presentation by John Dahldorf, chief financial officer, will begin at 11:15 a.m., Eastern Daylight Time (8:15 a.m., Pacific Daylight Time).

February 27, 2014
Can Near-Infrared Imaging Predict Heart Attack Risk?
Infraredx TVC Imaging System
What causes a heart attack? Is it a physical narrowing in the coronary artery, a blockage that can be seen on angiography? Or is it more likely the eruption of a lipid-rich plaque, a so-called vulnerable plaque, that may not look significant in percent stenosis during a standard catheterization? Today MedStar Heart Institute and Infraredx announced enrollment of the first patient in the Lipid-Rich Plaque (LRP) Study, which will involve 100 centers worldwide and has a target enrollment of 9,000 patients. As Infraredx founder Dr. James Muller states, "Once completed, the LRP Study could redefine the role of intravascular imaging and lay the groundwork for changing standard protocol for managing coronary artery disease."

February 26, 2014
Spring Training: Transradial Style
Baseball and U.S. map
No less than four U.S. training courses in Transradial Angioplasty have just been announced for this Spring (and, yes, Spring is actually going to come after this very long winter). And all of these training opportunities are being offered at no cost. The courses span the length and breadth of the United States. From East to West.


February 24, 2014
The Incredible Shrinking Cardiac Devices
Micra pacemaker in heart
The "world's smallest, minimally invasive cardiac pacemaker," Medtronic's Micra™ Transcatheter Pacing System, was implanted last week for the first time in the United States. This implantation comes just two-plus months after its first in-human implantation, performed in Austria. Both implantations are part of a single-arm multi-center clinical trial which will enroll up to 780 patients.

February 24, 2014
RENLANE™ Renal Denervation System from Cordis Gets CE Mark
Darrel Francis, MD
Even while panels and journals continue to debate the efficacy of renal denervation in treating resistent hypertension, a situation brought to the forefront by Medtronic's announcement in January that its pivotal U.S. renal denervation trial failed to meet its pre-specified endpoint, the Conformité Européenne has bestowed its CE Mark on a brand new system from Cordis Corporation.

February 24, 2014
Volcano Reports Fourth Quarter Revenues Increase Six Percent On A Constant Currency Basis
Volcano logo
Volcano Corporation (Nasdaq: VOLC) today reported results for the fourth quarter and all of 2013. For the quarter ended December 31, 2013, Volcano reported revenues of $103.3 million versus revenues of $102.5 million in the same period a year ago. On a constant currency basis, revenues increased six percent year-over-year after adjusting for a negative impact of approximately $5.5 million from foreign currency. The company reported a net loss on a GAAP basis of $20.5 million, or $0.38 per share, in the fourth quarter of 2013, versus net income of $2.5 million, or $0.04 per diluted share, in the same period a year ago.

February 20, 2014
Angioplasty Arrives in the Outback: First Stent Placed in Northern Territory
Australia - Northern Territory
It's been over 35 years since the first angioplasty was performed in Zurich by Dr. Andreas Gruentzig, but it was just yesterday that this minimally invasive procedure arrived in Australia's Northern Territory. As reported today by Sky News, Dr. Marcus Ilton, chief cardiologist at Royal Darwin Hospital, performed the first angioplasty and stent implantation ever done in the NT.

February 19, 2014
Medtronic Announces Global Launch of Miniature Cardiac Monitor, Reveal LINQ™ ICM
Medtronic's Reveal LINQ ICM compared to Reveal XT
Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance, CE (Conformité Européenne) Mark, and the global launch of its Reveal LINQ Insertable Cardiac Monitor (ICM) System, the smallest implantable cardiac monitoring device available for patients. The Reveal LINQ ICM is approximately one-third the size of a AAA battery (~1 cc), making it more than 80 percent smaller than other ICMs.

February 18, 2014
Medtronic Reports Third Quarter Earnings
Medtronic Headquarters
Medtronic, Inc. (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2014, which ended January 24, 2014. The company reported worldwide third quarter revenue of $4.163 billion, compared to the $4.027 billion reported in the third quarter of fiscal year 2013, an increase of 4 percent on a constant currency basis after adjusting for a $41 million negative foreign currency impact or 3 percent as reported.

February 13, 2014
Medtronic Launches New Peripheral Angioplasty Catheter in Europe
Medtronic's TOTAL across crossing catheter
Today Medtronic, Inc. (NYSE: MDT) announced the European launch of its latest product to address the problems of peripheral artery disease (PAD), the "TOTAL Across" crossing catheter, intended for use in the lower extremities, specifically those arterial blockages below the knee that often are the cause of critical limb ischemia. Today's announcement by Medtronic adds to their portfolio of peripheral devices, including the IN.PACT drug-eluting balloon, and several balloon catheters designed for use in challenging narrow below-the-knee blockages.

February 11, 2014
DUTCH PEERS: Third Generation Drug-Eluting Stents from Medtronic and Boston Scientific Are (Almost) Equivalent
Resolute Integrity vs. Promus Element
Are third generation drug-eluting stents interchangeable? And what exactly is a "third generation" drug-eluting stent anyway? These were questions addressed by the DUTCH PEERS randomized clinical trial, recently published in The Lancet. The results showed that the Resolute Integrity was non-inferior to the Promus Element. There was, however, one parameter in which the two stents were not the same: longitudinal stent deformation.

February 11, 2014
Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2014
Medtronic, Inc.
Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2014 on Tuesday, February 18, 2014. Medtronic will host a webcast at 7:00 a.m. CST to discuss financial results for its third quarter. The webcast can be accessed by clicking on the Investors link through the Medtronic website at www.medtronic.com on February 18, 2014.

February 9, 2014
Capsule-Sized Leadless Pacemakers May Lead the Way in Heart Rhythm Management
St. Jude's Nanostim leadless pacemaker
Is the future of implantable pacemakers a miniaturized leadless capsule, no bigger than a coin, delivered non-surgically via a catheter, much like a stent during angioplasty? Looking at the recent news from two of the leading manufacturers of pacemakers, one would conclude in the affirmative. Last week, St. Jude Medical announced the first U.S. implantation of their leadless Nanostim pacemaker (press release below) at Mt. Sinai Hospital in New York. The next-in-line challenger to St. Jude is Medtronic, who announced the first human implant of its leadless Micra catheter in December.

February 5, 2014
CVS To Stop Selling Cigarettes and Tobacco at a Cost of $2 Billion Annually
CVS Logo - CVS quits for good
CVS/pharmacy made an extraordinary announcement today: the company has decided to stop selling cigarettes and all tobacco products by October 1 of this year. As stated by Larry Merlo, President and CEO of CVS, "Tobacco products have no place in a setting where health care is delivered."


February 5, 2014
Boston Scientific Launches OffRoad™ Re-Entry Catheter System
Boston Scientific's OffRoad Re-Entry Catheter System
The OffRoad Re-Entry Catheter System is intended to help physicians navigate around complete arterial blockages by traveling within the tissue of the vessel wall (subintimal space). Once the catheter has passed the blockage, a unique conical-shaped positioning balloon is used to expand the subintimal space and direct a micro-catheter lancet to re-enter the vessel. This allows the physician to position a guidewire across the occlusion and to then treat the blockage using traditional endovascular techniques such as angioplasty and stenting.

February 4, 2014
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
Volcano Headquarters
Volcano Corporation (NASDAQ: VOLC) today announced that it will report its operating results for the fourth quarter of fiscal 2013 on Monday, February 24. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time (5 p.m., Eastern Standard Time), Monday, February 24, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer.

January 31, 2014
Ask George W. Bush a Question About His Stent…or Anything Else
Ask Bush a Question
Six months ago, former President Bush received an angioplasty and stent. The stent was recommended by Bush's doctors to open a blockage in one of his coronary arteries, found during his annual physical exam. The next week saw numerous articles in the mainstream media and professional publications questioning whether this stent was necessary. So…at this year's CRT 2014 meeting, held annually in Washington, D.C., Dr. Ron Waksman and the rest of the organizers have arranged for George W. Bush to be a featured speaker. And they have been emailing all potential attendees with the subject line, "Submit a Question for President Bush!"

January 28, 2014
Medtronic Relocates Its Regional Headquarters to Dubai
Dubai marina
Medtronic, Inc. (NYSE: MDT), the world's largest medical technology company, providing therapies to treat many conditions including cardiac and vascular diseases, diabetes, neurological and spinal conditions, today announced the relocation of its regional Middle East and Africa (MEA) headquarters to Dubai. The company will relocate all its regional operations to TECOM Investment's DuBiotech. DuBiotech is a freezone dedicated to facilitating and fostering growth of the life sciences industry in the United Arab Emirates (UAE).

January 28, 2014
FDA Approves Medtronic's Valiant Captivia Stent Graft for Treatment of Aortic Dissections
Valiant Captivia tip
Currently type B aortic dissections are managed in three ways: emergency open surgical repair, medical management, and endovascular repair. Today, the FDA approved a new indication for an endovascular device, the Valiant Captivia Thoracic Stent Graft System, made by Medtronic, based on the positive results of the DISSECTION Trial. The trial met its primary safety endpoint by achieving an 8% all-cause mortality rate at 30 days, which represents, according to the company's press release, a three-to-four-fold mortality improvement over open surgical repair.

January 27, 2014
$3.4 Million Grant to Saint Luke's Mid America Heart Institute for Chronic Total Occlusion PCI Study
Chronic total occlusions (CTO) historically have been one of the most difficult and challenging areas for minimally invasive treatment with angioplasty and stents. This $3.4 million grant being given to Saint Luke's Mid America Heart Institute by Boston Scientific will aid in helping to "better define the success, safety, health benefits, and cost-effectiveness of novel methods to open challenging blocked coronary arteries previously thought untreatable through minimally invasive techniques."

January 23, 2014
Boston Scientific Names Dr. Craig Thompson Chief Medical Officer for Interventional Cardiology
Craig Thompson, MD
Boston Scientific started off its New Year by naming Craig A. Thompson, MD, MMSc, as the new Chief Medical Officer for Interventional Cardiology. Dr. Thompson is well-known to the field, having served as Director of the Cardiovascular Catheterization Laboratory at the Dartmouth-Hitchcock Medical Center and most recently Director, Invasive Cardiology and Vascular Medicine at Yale New Haven Hospital. Dr. Thompson has presented regularly at professional symposia and specifically on two topics that we at Angioplasty.Org have been covering for some time: intravascular ultrasound (IVUS) and the transradial approach to diagnostic and interventional procedures.

January 17, 2014
FDA Approves Medtronic's CoreValve; Device Available Immediately in U.S.
Medtronic's CoreValve
This morning the U.S. Food and Drug Administration approved Medtronic's self-expanding transcatheter CoreValve® system for patients who are too sick to withstand traditional aortic valve replacement open heart surgery. Although an approval had been expected during the first half of this year, today's announcement took the cardiology community by surprise. The CoreValve sytem is now the second transcatheter aortic valve device available in the U.S., breaking the monopoly currently enjoyed by the Edwards Sapien valve for high risk patients. A Medtronic spokesperson confirmed to Angioplasty.Org that the CoreValve is available as of today for use in the United States.

January 16, 2014
50 Years Ago Today Charles Dotter Invented Angioplasty
Charles Dotter, MD
It was 50 years ago today that Dr. Charles T. Dotter, a radiologist in Portland, Oregon, performed the first angioplasty. But it wasn't in the heart; it was in the leg. An 82-year-old woman was suffering from great pain in her left foot because of blocked circulation in her leg. Her toes had become gangrenous and there was an non-healing ulcer. Amputation was recommended by the physicians at Oregon Health Sciences University, but the woman refused. A video clip from my documentary "Explorers of the Heart" tells more.

January 15, 2014
Edwards and Medtronic: "Valve Wars"
Medtronic and Edwards logos
A decade ago it was "stent wars"; now it's "valve wars." Percutaneous transcatheter aortic valve replacements to be exact: also called TAVR or TAVI. With these new devices, an aortic valve replacement (or implantation) can be accomplished using catheter-based techniques similar to coronary angioplasty, and without the need for open surgery. And when the competition is fierce, the patent suits appear: today a federal jury handed a victory to Edwards, finding "willful infringement" by Medtronic of Edwards' Cribier patent, and awarding $394 million in damages. Medtronic immediately announced that it would appeal the verdict.

January 13, 2014
Another Viewpoint on Renal Denervation and SYMPLICITY HTN-3 from Dr. Darrel Francis
Dr. Darrel Francis
Is the failure of the SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation? Will renal denervation now land on the heap of failed technologies? I don't think so, and Dr. Darrel Francis, the cardiologist who famously predicted that SYMPLICITY HTN-3 would not meet its endpoint, agrees. In fact Dr. Francis told Angioplasty.Org that it would be a "grave error" if the FDA withheld renal denervation from the American people, based on this news! OK. Do I have your attention?

January 13, 2014
Volcano Corporation Announces Preliminary Fourth Quarter 2013 Revenues; Year-Over-Year Annual Revenues Increase Eight Percent On A Constant Currency Basis
Volcano logo
Volcano Corporation (Nasdaq: VOLC) said today that it expects total revenues on a reported basis for the fourth quarter of 2013 will be approximately $103.3 million, bringing expected full year 2013 revenues on a reported basis to approximately $393.7 million—in line with most recent guidance. Revenues for the fourth quarter of 2013 reflect an increase of one percent and six percent on a reported basis and constant currency basis, respectively, compared to the fourth quarter a year ago.

January 9, 2014
Medtronic's U.S. Renal Denervation Trial Fails to Meet Efficacy Endpoint
Renal sympathetic nerves and the kidney
In a definite blow to the entire field of renal denervation, Medtronic reported this morning that its pivotal U.S. clinical trial for the Symplicity™ Renal Denervation System has failed to meet its endpoint for efficacy. Pending review by a panel of invited experts, the company has suspended enrollment in all of its renal denervation clinical studies worldwide. Dr. Rick Kuntz, chief medical officer for Medtronic, stated: "We believe this course of action is the most prudent and will help us thoroughly evaluate these findings and determine the appropriate next steps for renal denervation therapy."

January 6, 2014
Volcano Corporation Presentation At J.P. Morgan Conference To Be Webcast
Volcano HQ in San Diego
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15. The presentation by Scott Huennekens, president and chief executive officer, will begin at 3:30 p.m., Pacific Standard Time (6:30 p.m., Eastern Standard Time).

Click here for more information about the following ads